By Carla K. Johnson

Here we go again: COVID-19 hospital admissions have inched upward in the United States since early July in a small-scale echo of the three previous summers.

With an updated vaccine still months away, this summer bump in new hospitalizations might be concerning, but the number of patients is far lower than before. A look at what we know:

HOW BAD IS THE SPIKE?

For the week ending July 29, COVID-19 hospital admissions were at 9,056. That's an increase of about 12% from the previous week.

But it's a far cry from past peaks, like the 44,000 weekly hospital admissions in early January, the nearly 45,000 in late July 2022, or the 150,000 admissions during the omicron surge of January 2022.

“It is ticking up a little bit, but it’s not something that we need to raise any alarm bells over,” said Dr. David Dowdy, an infectious disease epidemiologist at Johns Hopkins Bloomberg School of Public Health.

It’s likely that infections are rising too, but the data is scant. Federal authorities ended the public health emergency in May, so the Centers for Disease Control and Prevention and many states no longer track the number of positive test results.

WHAT ABOUT DEATHS?

Since early June, about 500 to 600 people have died each week. The number of deaths appears to be stable this summer, although past increases in deaths have lagged behind hospitalizations.

HOW ARE WE TRACKING THE VIRUS?

The amount of the COVID-19 virus in sewage water has been rising since late June across the nation. In the coming weeks, health officials say they'll keep a close eye on wastewater levels as people return from summer travel and students go back to school.

Higher levels of COVID-19 in wastewater concentrations are being found in the Northeast and South, said Cristin Young, an epidemiologist at Biobot Analytics, the CDC's wastewater surveillance contractor.

“It’s important to remember right now the concentrations are still fairly low,” Young said, adding it's about 2.5 times lower than last summer.

And while one version of omicron — EG.5 — is appearing more frequently, no particular variant of the virus is dominant. The variant has been dubbed “eris” but it’s an unofficial nickname and scientists aren’t using it.

“There are a couple that we’re watching, but we’re not seeing anything like delta or omicron,” Young said, referencing variants that fueled previous surges.

And mutations in the virus don't necessarily make it more dangerous.

“Just because we have a new subvariant doesn’t mean that we are destined to have an increase in bad outcomes," Dowdy said.

WHEN IS THE NEW VACCINE COMING?

This fall, officials expect to see updated COVID-19 vaccines that contain one version of the omicron strain, called XBB.1.5. It’s an important change from today’s combination shots, which mix the original coronavirus strain with last year’s most common omicron variants.

It's not clear exactly when people can start rolling up their sleeves for what officials hope is an annual fall COVID-19 shot. Pfizer, Moderna and smaller manufacturer Novavax all are brewing doses of the XBB update but the Food and Drug Administration will have to sign off on each, and the CDC must then issue recommendations for their use.

Dr. Mandy Cohen, the new CDC director, said she expects people will get their COVID-19 shots where they get their flu shots — at pharmacies and at work — rather than at dedicated locations that were set up early in the pandemic as part of the emergency response.

“This is going to be our first fall and winter season coming out of the public health emergency, and I think we are all recognizing that we are living with COVID, flu, and RSV," Cohen told The Associated Press last week. “But the good news is we have more tools than ever before.”

AP Medical Writers Lauran Neergaard and Mike Stobbe contributed to this report.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

Share:
More In Science
Wearable for Walking Impairments; Plant-Based Wound Gel
On this episode of Cheddar Innovates: Evolution Devices CEO breaks down how the Evowalk wearable device can help those with walking impairments; Cresilon CEO explains how he's created a plant-based gel to easily treat wounds in both humans and animals; A look at Curiosity Stream's 'The Colorado Problem.'
How This Plant-Based Gel Can Treat Wounds
Joe Landolina, CEO and Co-Founder of Cresilon, joins Cheddar Innovates to discuss how he's created a plant-based gel to easily treat wounds in both humans and animals.
Western Drought Worst In 1,200 Years
A new analysis reveals that for more than two decades, the West has been the driest it has ever been since 800 A.D. The drought which began in 2000 has brought more devastating wildfires and draining water reserves well below healthy levels. Climate Scientists and Adjunct Associate Research Scientist at Lamont Doherty Earth Observatory at Columbia University,Benjamin Cook, joined Cheddar to discuss more.
Energy Vault Begins Trading on the NYSE Following SPAC Merger
Energy Vault, the company developing sustainable, grid-scale energy storage solutions, is now trading on the New York Stock Exchange following the completion of its business combination with Novus Capital Corporation II. Energy Vault develops sustainable, grid-scale energy storage solutions designed to advance the transition to a carbon free, resilient power grid. Robert Piconi, co-founder and CEO of Energy Vault, joins Cheddar News' Closing Bell to disucss.
Large Companies Accused of Exaggerating Climate Actions
In an effort to fight climate change several corporations have vowed to work to fight climate change by 2030. They say the goal is to reduce carbon emissions by 40% or even close to 100%. However, according to a new study, many of these companies are not actually practicing what they preach. Tom Egger, senior lecturer at Emeritus at the University of Wisconsin, joins Cheddar News to discuss more.
Getlabs Raises $20 Million to Expand At-Home Lab Appointments Nationwide and Launches API
At-home medical labs company Getlabs raised $20 million in a Series A round, led by Emerson Collective and the Minderoo Foundation. Getlabs aims to be the boots-on-the-ground partner to telehealth. The company says more than 70% of medical decisions still require collecting diagnostic tests in person, and that it fills that void by delivering health care directly to their patients' homes. Founder & CEO of Getlabs Kyle Michelson joined Cheddar News' Closing Bell to discuss.
Innovation in Eyecare; Tech to Detect Cancer in Pets
On this episode of Cheddar Innovates: WALDO CEO breaks down why now is a good time to make eyecare a priority, and how they are democratizing access to eyecare for all; COO at PetDx explains how next-generation sequencing technology is being used to detect cancer in pets early; Cheddar gets a look at Curiosity Stream's 'Inside The Mind of a Con Artist.'
Load More